EZH2 and breast carcinoma: Clinically, the use of EZH2 inhibitors in combination with IO represents a compelling strategy to remodel the TME, potentially overcoming immune evasion and enhancing therapeutic outcomes in breast cancer (16), mesothelioma (45), non-Hodgkin lymphoma (46) and other cancers.